Last reviewed · How we verify
Adenosine deaminase deficiency — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Revcovi | ELAPEGADEMASE | Leadiant Biosci Inc | 2018-01-01 | |||
| Adagen | Adagen | Leadiant Biosciences, Inc. |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Adenosine deaminase deficiency
- Leadiant Biosci Inc · 1 drug in Adenosine deaminase deficiency
- Leadiant Biosciences, Inc. · 1 drug in Adenosine deaminase deficiency
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Adenosine deaminase deficiency:
- Adenosine deaminase deficiency treatment updates — RSS
- Adenosine deaminase deficiency treatment updates — Atom
- Adenosine deaminase deficiency treatment updates — JSON
Cite this brief
Drug Landscape (2026). Adenosine deaminase deficiency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adenosine-deaminase-deficiency. Accessed 2026-06-10.
Related
- Adenosine deaminase deficiency full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing